Patent · US Active

Compositions and methods for transient delivery of nucleases

US11920168B2 · kind B2 · utility

0Cited by
28References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 29, 2020
Grant dateMar 5, 2024
Priority date
Expiry dateOct 8, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2750/14143
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The disclosure in some aspects relates to recombinant adeno-associated viruses having nuclease grafted to one or more capsid proteins. In some aspects, the disclosure relates to isolated AA V capsid proteins having terminally grafted nucleases and isolated nucleic acids encoding the same. Recent approaches to delivering nucleases to cells for gene editing have focused on delivering of expression vectors engineered to express the nucleases in target cells. However, these approaches have proved to be problematic in many instances due to genotoxicity resulting from to prolonged expression of gene editing system in vivo. To prevent such off-target genotoxicity due to prolonged presence of a gene editing system, several studies explored delivery of mRNA or protein instead of delivering the gene coding for the nucleases in cell culture.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.